Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas

Penglei Zhu; Hao Wu; Buyi Zheng; Hua Wang; Yi Zou

doi:10.1007/s12672-024-01025-w

Elucidating the impact of parthanatos-related microRNAs on the tumoral immune microenvironment and clinical outcome in low-grade gliomas

Discov Oncol. 2024 May 10;15(1):153. doi: 10.1007/s12672-024-01025-w.

Authors

Penglei Zhu¹, Hao Wu¹, Buyi Zheng¹, Hua Wang², Yi Zou³

Affiliations

¹ Department of Neurosurgery, Wenzhou People's Hospital, No.299, Gushan Road, Ouhai District, Wenzhou, 325000, Zhejiang, China.
² Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Ouhai District, Wenzhou City, 325000, Zhejiang, China.
³ Department of Neurosurgery, Wenzhou People's Hospital, No.299, Gushan Road, Ouhai District, Wenzhou, 325000, Zhejiang, China. 15958725801@163.com.

Abstract

Parthanatos, a cell death mechanism triggered by PARP-1 activation, is implicated in oncogenic processes, yet their role in low-grade gliomas (LGG) remains poorly understood. This research investigates Parthanatos-related miRNAs' prognostic and immunomodulatory potential, alongside their influence on therapeutic outcomes in LGGs. Comprehensive miRNA and mRNA profiles of LGG patients were extracted from TCGA and CGGA databases, integrating clinical parameters to identify Parthanatos-associated miRNAs. IHC data validated the expression levels of Parthanatos-related genes in glioma versus normal brain tissues. Protein-protein interaction networks and Spearman correlation analysis facilitated the identification of key miRNAs. Parthanatos-related miRNA indices (PMI) were screened using Lasso and assessed for their accuracy in predicting prognosis, comparing their associated potential molecular functions and heterogeneity of the immune microenvironment. Drug sensitivity was assessed between different groups and optimal therapeutic agents were predicted. Validate the expression levels of key miRNAs by qPCR. Ninety-one miRNAs significantly associated with Parthanatos were screened, through which a PMI prognosis model of nine miRNAs was constructed. The PMI score was able to independently predict the prognosis of patients with LGG, and the nomogram constructed based on the PMI provided a practical tool for clinical prediction of patient prognosis. The proportion of immune response was lower in patients in the high-risk group, and there were significant differences in drug sensitivity between different risk classes, while drugs such as Fasudil were identified as the most promising therapeutic agents for patients in the high-risk group. Our findings highlight the critical role of Parthanatos-associated miRNAs in the progression and treatment of LGG, offering novel insights into their prognostic value and therapeutic potential.

Keywords: Immune microenvironment; Low-grade glioma; Parthanatos; Personalized therapy; Prognostic model; microRNA.